Empowered Patient Podcast Developing Precision Inhaled Therapy to Treat Pulmonary Arterial Hypertension with Lisa Yanez Aerami Therapeutics
Lisa Yanez is the CEO of Aerami Therapeutics, a clinical stage biopharmaceutical company focused on the rare cardiopulmonary disease pulmonary arterial hypertension. Early studies show that using this smart breath-activated inhalation delivery system to administer AER901, inhaled Imatinib reduces side effects and requires less frequent administration by those suffering from PAH.
Lisa explains, "Our company is focused on a rare disease, pulmonary arterial hypertension. There was a drug that was an oral drug that was studied before, but due to the side effects, that trial ceased. That said, if you look at the efficacy of that drug, it was one of the best-performing drugs ever for these patients. It didn't just help with symptoms. It also helped the underlying cause of the disease. What our company has decided to do is take a very intelligent inhaled patient-proven device and couple it with this product to generate the best of both worlds. What we're trying to do is helping patients live longer, but our mission is also helping patients live better."
"One of the reasons I've fallen in love with this particular condition is because it mostly impacts women of childbearing age. They go about two years not knowing what's wrong with them. They have shortness of breath, they have a lot of fatigue, they're very dizzy, and sometimes they pass out. They go to all these different doctors, and typically it does take two years, and people think they're crazy."
"Then, once they're diagnosed, there are 15 approved therapies. Even then, there's only a five to seven-year time span in terms of survival. And so, there's a lot more that needs to be done with these particular patients."
@AeramiTx #Aerami #Cardiopulmonary #RareDisease #PulmonaryArterialHypertension #PulmonaryHypertension #PAH #PH #HeartDisease #LungDisease #AER901 #InhaledTherapeutics #AER601